Answers are grounded in this paper and cite their sources.
Objective: Omalizumab safety studies have shown that the drug has an excellent safety profile and is well tolerated in patients with asthma and chronic idiopatic urticaria (CIU) with no blood chemistry monitoring during treatment. Although our clinical experience with drug has pointed out abnormalities in amylase levels. The aim of the present study is to assess blood amylase values during omalizumab therapy and to explain if there is an association between omalizumab therapy and high serum amylase levels.
No takes yet. Share an insight, caveat, or question.
Karabıber et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: